Centre Antoine Lacassagne
- Address
- lock Available on a paid plan
Centre Antoine Lacassagne - Comprehensive Cancer Research Institute
Centre Antoine Lacassagne stands as a leading comprehensive cancer research center, conducting advanced clinical trials across a diverse spectrum of oncological conditions. The center demonstrates particular expertise in immunotherapy, targeted therapy, and precision oncology, with extensive experience in novel therapeutic combinations and biomarker-driven treatment strategies.
- Genitourinary cancers including bladder cancer, prostate cancer, and renal cell carcinoma with focus on immunotherapy combinations and molecular profiling
- Breast cancer research including HER2-positive disease and brain metastases treatment optimization
- Gastrointestinal malignancies encompassing colorectal, pancreatic, esophageal, and anal cancers with innovative chemotherapy and immunotherapy approaches
- Thoracic oncology including non-small cell lung cancer with radiotherapy-immunotherapy combinations
- Hematologic malignancies including acute myeloid leukemia, lymphomas, and myeloproliferative neoplasms
- Central nervous system tumors including gliomas and meningiomas with novel targeted agents
- Head and neck cancers, gynecologic malignancies, and rare tumors including neuroendocrine tumors and sarcomas
The center excels in conducting complex Phase I through Phase III trials, with particular emphasis on checkpoint inhibitor combinations, antibody-drug conjugates, and molecular residual disease monitoring. Research programs integrate advanced imaging techniques, including PSMA PET/CT, with circulating tumor DNA analysis and comprehensive genomic profiling. The center's expertise extends to dose optimization studies, particularly in patients with enzyme deficiencies, and innovative approaches to treatment de-escalation in selected patient populations.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 5 of 22 therapeutic areas and 15 of 300 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 290 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 978 other sites in France
Therapeutic Area Benchmark — France
Select a therapeutic area to compare against other sites in France.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: France
Market Share
Country: France
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Centre Antoine Lacassagne
lock Showing 1 of 290 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| (20289) A Phase 2 Basket Study of the Oral TRK Inhibitor larotrectinib in Subjects with NTRK Fusion-Positive Tumors | Bayer AG, Bayer Consumer Care AG | Phase II | Not Recruiting | Jun 2016 | Sep 2025 |
IMP list
lock Showing 1 of 300 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Pembrolizumab | 43 | Unknown | 2016-09-16 | 2026-06-11 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.